Abramson Cancer Center at Penn Medicine: Neoplasms trials

The registry lists 32 Neoplasms studies with Abramson Cancer Center at Penn Medicine as lead sponsor. 7 are open to participants now and 5 have results posted.

Early Phase 1 2Phase 1 7Phase 2 2Phase 3 1No phase 20(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Saruparib in HRDsig+ Solid TumorsNot yet recruitingNCT07832630Phase 2
• Genetic Information for Families After Tumor Testing StudyEnrolling by invitationNCT07517666Not applicable
• Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3)RecruitingNCT07471958
• Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)RecruitingNCT07454499Not applicable
• Assessing Perceptions of ML Explanations by Medical OncologistsEnrolling by invitationNCT06699615Not applicable
• Autoimmunity After Checkpoint BlockadeRecruitingNCT04119713
• The Radiation Oncology Registry and Biosample RepositoryRecruitingNCT01577251
• Virtual Reality to Promote Relaxation Prior to SimulationCompletedNCT06318338Not applicableResults posted
• Behavioral Economic Strategies to Improve PRO AdherenceCompletedNCT06013176Not applicableResults posted
• PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI CancersCompletedNCT04616768Phase 3Results posted
• RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic CancersCompletedNCT02303990Phase 1Results posted
• Phase II Maraviroc for GVHD PreventionCompletedNCT01785810Phase 2Results posted
• Using Surveys to Examine the Association of Exposure to ML Mortality Risk Predictions With Medical Oncologists' Prognostic Accuracy and Decision-makingCompletedNCT06463977
• Penn Medicine Biobank Return of Results ProgramActive, not recruitingNCT06089954Not applicable
• eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary CancerActive, not recruitingNCT05427240Not applicable
• Understanding Quality of Life Among Patients With Cancer Receiving Palliative CareActive, not recruitingNCT05331625Not applicable
• The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer PatientsActive, not recruitingNCT05226078Not applicable
• TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)TerminatedNCT04873895Phase 1
• Multimodality MRI and Liquid Biopsy in GBMWithdrawnNCT04776980Early Phase 1
• Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer PatientsCompletedNCT04353973Not applicable
• Yoga for Solid TumorWithdrawnNCT03728205Not applicable
• A PHASE I, SINGLE-CENTER, MIXED METHODS STUDY ON THE HEALTH OUTCOMES OF VISUAL SELF EXPRESSIONCompletedNCT03155672
• Assessing the Impact of Electronic Capture of Patient Reported Outcomes in Radiation OncologyCompletedNCT02756767
• Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid TumorsCompletedNCT02225002Phase 1
• Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic DiseasesActive, not recruitingNCT02159742
• Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid TumorsCompletedNCT02157831Early Phase 1
• HPPH and PDT for Pleural MalignancyCompletedNCT01673074Phase 1
• DIBH Proton PlanningCompletedNCT01386697
• Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) StudyCompletedNCT01212731
• Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to TreatmentCompletedNCT00909831Phase 1
• Infusional C-myb ASODN in Advanced Hematologic MalignanciesCompletedNCT00780052Phase 1
• Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00714181Phase 1